Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment
Status:
Completed
Trial end date:
2020-07-13
Target enrollment:
Participant gender:
Summary
Comparison of the pharmacokinetics/Pharmacodynamics of the HSK3486 in Patients With Mild and
Moderate Hepatic Impairment Compared with Healthy Volunteers
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan Haisco Pharmaceutical Group Co., Ltd Sichuan Haisco Pharmaceutical Group Co., Ltd.
Collaborators:
First Hospital of Jilin University The First Hospital of Jilin University